When should patients with diabetes mellitus be screened for osteoporosis?

Discuss the cases and questions guidelines don't cover.

Related Questions

Under what circumstances would you consider a bone biopsy in the workup of renal osteodystrophy?

Do you foresee any added benefit of triple agonist therapy (GLP-1, GIP and glucagon) for glycemic control in patients with Type 1 diabetes mellitus?

In patients with history of breast cancer on aromatase inhibitor therapy, when do you transition off zolendronic acid therapy?

Would you consider SGLT2i therapy as a second line agent for treatment of HNF1A-MODY (MODY 3)?

Is there a lifetime cap on the use of Reclast infusions for treatment of osteoporosis?

Evidence Meets Expertise